Lymphoma, T-Cell, Cutaneous
Conditions
Keywords
Lymphoma, Cutaneous Lymphoma, cutaneous T-cell lymphoma (CTCL), CD30-Positive Cutaneous Lymphoma, T-cell lymphoma, PTCL, CTCL, CD30, immunotherapy
Brief summary
The investigators plan to investigate AFM13 and evaluate its ability to facilitate and redirect the Natural Killer (NK) cells in eliminating CD30-positive lymphoma targets in the skin and, by inference, other organs involved by the lymphoma.
Detailed description
This is an open label, Phase Ib/IIa study designed to evaluate the biologic activity of AFM13 in patients with relapsed or refractory CD30-positive lymphomas with cutaneous involvement. Primary cutaneous CD30-positive lymphoproliferative disorders (LPD) represent a spectrum from lymphomatoid papulosis (LyP), to primary cutaneous anaplastic large cell lymphoma (C-ALCL), to transformed mycosis fungoides (TMF). The most indolent form of primary cutaneous CD30-positive LPD is LyP, which is usually well controlled with low dose oral methotrexate, but control of the disease frequently requires life-long therapy. In contrast, TMF is an aggressive disease which does not have a standard of care, as patients are treated with various modalities of care with variable outcomes). The spectrum of other CD30-positive lymphomas with cutaneous presentation is very broad and involves systemic B and T cell lymphomas with various clinical behaviors. Redirecting Natural Killer (NK) cells towards these CD30-positive malignancies through direct engagement with AFM13 is expected to induce tumor cell killing through NK cell-mediated and T cell-mediated cytotoxicity (i.e., cytotoxic T lymphocytes (CTL)). The primary objective of this trial is to study the biologic and immunologic effects induced by the administration of various doses of AFM13, when given as a single agent.
Interventions
DRUGAFM13
AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
Sponsors
Ahmed Sawas
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years * Histologically confirmed CD30-positive lymphoma with cutaneous involvement * Failure or intolerance to at least one prior therapy for the current disease * Presence of one or more cutaneous lesions (measuring at least 1 cm x 1 cm in size; if only one lesion is present it should be up to the investigator discretion to determine eligibility) * Eastern Cooperative Oncology Group (ECOG) performance status ≤2 * Adequate organ and marrow function * Platelets ≥50,000/μL * Absolute neutrophil count ≥ 1,000/μL * Bilirubin \< 1.5 x institutional upper limit of normal (ULN) or \< 3 x ULN in patients with Gilbert's disease or liver involvement * Serum albumin ≥ 2.0 g/dL * Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) ≤2.5 × institutional ULN or, in the case of liver involvement by the primary disease AST/ALT ≤ 5 x ULN * Creatinine≤1.5 x institutional ULN or estimated creatinine clearance of ≥45 mL/min by the Cockcroft-Gault equation or measured creatinine clearance \>45 mL/min * Females of child bearing potential must have a negative serum pregnancy test with 7 days prior to first dose of treatment. Female patients of childbearing potential and all male partners must agree to use double barrier methods of contraception throughout the study period and for at least 30 days following investigational product discontinuation. * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* Any cancer-related therapy for the current disease within 2 weeks of screening (all supportive care measures are allowed) * Major surgery within 2 weeks prior to first dose of study drug * Evidence of active central nervous system (CNS) involvement * Requirement for systemic immunosuppressive therapy (e.g. Graft-versus-Host Disease (GVHD) therapy within 12 weeks before the first dose of study drug) * Uncontrolled concurrent serious illness. * Concurrent malignancy or history of a previous malignancy within 3 years prior to first dose of the current study, unless curatively resected basal, squamous cell carcinoma of the skin, or cervical carcinoma in situ. * Active infections including hepatitis B carrier status, hepatitis C virus (HCV) infection (patients must have a negative Hepatitis B and Hepatitis C viral load at screening) * Known HIV-positive status * Any significant medical conditions, laboratory abnormality, or psychiatric illness that would exclude the subject from participation or interfere with study treatment, monitoring and compliance such as: * unstable angina pectoris, symptomatic congestive heart failure (New York Heart Association (NYHA) III or IV), myocardial infarction ≤ 6 months prior to first study drug, clinically significant and uncontrolled cardiac arrhythmia (e.g. atrial fibrillation/flutter ventricular cardiovascular physiology is allowed), cerebrovascular accidents ≤ 6 months before study drug start * severely impaired lung function * Serious, systemic infection requiring treatment ≤7 days before the first dose of study drug * Any severe, uncontrolled disease or condition which in the investigator's opinion, may put the subject at significant risk, may confound the study results, or impact the subject's participation in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Up to 2 years | Incidence of Treatment-Emergent Adverse Events \[Safety and Toxicity\] broken down by adverse event and CTCAE v4.0 grade of each event. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) | Up to 2 years | The sum of patients with partial responses and complete responses. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1 1.5 mg/kg of AFM13 once weekly for weeks 1-8.
AFM13: AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed. | 3 |
| Cohort 2 7.0 mg/kg of AFM13 once weekly for weeks 1-8.
AFM13: AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed. | 3 |
| Cohort 3 7.0 mg/kg CIVI of AFM13 once weekly for weeks 1-8.
AFM13: AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed. | 3 |
| Cohort 4 200 mg ( Flat dose) of AFM13 once weekly for weeks 1-8.
AFM13: AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed. | 6 |
| Total | 15 |
Baseline characteristics
| Characteristic | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 0 Participants | 1 Participants | 1 Participants | 3 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants | 3 Participants | 2 Participants | 5 Participants | 12 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 2 Participants | 2 Participants | 2 Participants | 6 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 3 Participants | 1 Participants | 1 Participants | 4 Participants | 9 Participants |
| Region of Enrollment United States | 3 participants | 3 participants | 3 participants | 6 participants | 15 participants |
| Sex: Female, Male Female | 1 Participants | 1 Participants | 1 Participants | 2 Participants | 5 Participants |
| Sex: Female, Male Male | 2 Participants | 2 Participants | 2 Participants | 4 Participants | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 1 / 3 | 0 / 3 | 0 / 6 |
| other Total, other adverse events | 0 / 3 | 3 / 3 | 0 / 3 | 0 / 6 |
| serious Total, serious adverse events | 1 / 3 | 1 / 3 | 0 / 3 | 0 / 6 |
Outcome results
Primary
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
Incidence of Treatment-Emergent Adverse Events \[Safety and Toxicity\] broken down by adverse event and CTCAE v4.0 grade of each event.
Time frame: Up to 2 years
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1 | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | G3/4 Infection and skin rash | 1 Participants |
| Cohort 1 | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | G1 IRR | 0 Participants |
| Cohort 1 | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Death, G3 infection , IRR | 0 Participants |
| Cohort 1 | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | No AE | 2 Participants |
| Cohort 2 | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | G1 IRR | 2 Participants |
| Cohort 2 | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Death, G3 infection , IRR | 1 Participants |
| Cohort 2 | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | No AE | 0 Participants |
| Cohort 2 | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | G3/4 Infection and skin rash | 0 Participants |
| Cohort 3 | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Death, G3 infection , IRR | 0 Participants |
| Cohort 3 | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | G1 IRR | 0 Participants |
| Cohort 3 | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | No AE | 3 Participants |
| Cohort 3 | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | G3/4 Infection and skin rash | 0 Participants |
| Cohort 4 | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | No AE | 6 Participants |
| Cohort 4 | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | G1 IRR | 0 Participants |
| Cohort 4 | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | G3/4 Infection and skin rash | 0 Participants |
| Cohort 4 | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Death, G3 infection , IRR | 0 Participants |
Secondary
Overall Response Rate (ORR)
The sum of patients with partial responses and complete responses.
Time frame: Up to 2 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1 | Overall Response Rate (ORR) | 2 Participants |
| Cohort 2 | Overall Response Rate (ORR) | 0 Participants |
| Cohort 3 | Overall Response Rate (ORR) | 2 Participants |
| Cohort 4 | Overall Response Rate (ORR) | 2 Participants |